Announcements
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
Increased expression of GRP94 protein is associated with decreased sensitivity to adriamycin in ovarian carcinoma cell lines
Show Less
1
Department of Gynecology and Obstetrics, Second Affiliated Hospital of Harbin Medical University, Harbin
2
Department of General Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin (China)
Clin. Exp. Obstet. Gynecol. 2008, 35(4), 264–266;
Published: 10 December 2008
Abstract
Purpose: This study examined the involvement of glucose regulated protein 94 (GRP94) in chemotherapy-resistance in human ovarian cancer cells. Methods: Three human ovarian cancer cells were examined for basal levels of GRP94 mRNA by RT-PCR and protein by Western blotting. Sensitivities to adriamycin of these cell lines were determined by means of MTT assay. The suppression of GRP94 expression was performed using specific siRNA in HO-8910PM cells, and cell apoptosis was assessed by flow cytometry. One-way ANOVA and the Student-Newman-Keuls test were used to determine which were significantly different. Results: HO-8910PM cells, with the highest basal levels of GRP94, exhibited the lowest sensitivity to adriamycin. In HO-8910PM cells, the sensitivity to adriamycin was increased when the GRP94 gene was disturbed by specific siRNA transfection. Conclusions: High GRP94 expression might be one of the molecular mechanisms causing resistance to adriamycin, and therefore GRP94 siRNA maybe useful in tumor-specific gene therapy in ovarian cancer.
Keywords
Glucose regulated protein 94
Adriamycin-resistance
Human ovarian cancer cells
siRNA